Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 2.7.10.2 - non-specific protein-tyrosine kinase

for references in articles please use BRENDA:EC2.7.10.2
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
IUBMB Comments
Unlike EC 2.7.10.1, receptor protein-tyrosine kinase, this protein-tyrosine kinase does not have a transmembrane domain. In the human genome, 32 non-specific protein-tyrosine kinases have been identified and these can be divided into ten families .
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
UNIPROT: O60674
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
The enzyme appears in viruses and cellular organisms
Synonyms
bcr-abl, focal adhesion kinase, c-abl, zap-70, src kinase, janus kinase, v-src, ephb4, p56lck, bruton's tyrosine kinase, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Jak2 protein
-
Janus kinase
-
receptor-associated kinase JAK2
-
tyrosine-protein kinase JAK2
-
70 kDa zeta-associated protein
-
-
-
-
ACTR-IIB
-
-
-
-
ACTRIIA
-
-
-
-
Agammaglobulinaemia tyrosine kinase
-
-
-
-
Amylovoran biosynthesis membrane-associated protein amsA
-
-
-
-
ATK
-
-
-
-
B cell progenitor kinase
-
-
-
-
B lymphocyte kinase
-
-
-
-
B-cell/myeloid kinase
-
-
-
-
BCR-ABL tyrosine kinase
-
-
-
-
BMK
-
-
-
-
BMP type II receptor
-
-
-
-
BMP-2/BMP-4 receptor
-
-
-
-
Bone marrow kinase BMX
-
-
-
-
BPK
-
-
-
-
Breast tumor kinase
-
-
-
-
Bruton's tyrosine kinase
-
-
-
-
c-ABL
-
-
-
-
c-FER
-
-
-
-
C-FES
-
-
-
-
C-SRC
-
-
-
-
C-SRC kinase
-
-
-
-
C-YES
-
-
-
-
CADTK
-
-
-
-
CAK beta
-
-
-
-
Calcium-dependent tyrosine kinase
-
-
-
-
Cell adhesion kinase beta
-
-
-
-
D-ash
-
-
-
-
DFer
-
-
-
-
Dsrc28C
-
-
-
-
ectoprotein kinase
-
-
-
-
Epithelial and endothelial tyrosine kinase
-
-
-
-
EPS I polysaccharide export protein epsB
-
-
-
-
focal adhesion kinase 1
-
-
-
-
gene lck protein kinase
-
-
-
-
gene lck tyrosine kinase
-
-
-
-
Hematopoietic consensus tyrosine-lacking kinase
-
-
-
-
Hemopoietic cell kinase
-
-
-
-
IL-2-inducible T-cell kinase
-
-
-
-
Itk
-
-
-
-
JAK protein tyrosine kinase
-
-
-
-
Kinase EMB
-
-
-
-
Kinase EMT
-
-
-
-
Kinase TLK
-
-
-
-
kinase, protein (phosphorylating tyrosine)
-
-
-
-
kinase, protein p56lck (phosphorylating)
-
-
-
-
L-JAK
-
-
-
-
Lck Tyrosine kinase
-
-
-
-
Leukocyte janus kinase
-
-
-
-
LSK
-
-
-
-
nonreceptor protein tyrosine kinase
-
-
-
-
NTK38
-
-
-
-
Nuclear tyrosine protein kinase RAK
-
-
-
-
ORF6
-
-
-
-
p150
-
-
-
-
p55-BLK
-
-
-
-
P55-FGR
-
-
-
-
p56-HCK
-
-
-
-
p56-HCK/p59-HCK
-
-
-
-
P56-LCK
-
-
-
-
p56lck kinase
-
-
-
-
p56lck protein kinase
-
-
-
-
p56lck protein tyrosine kinase
-
-
-
-
p56lck tyrosine kinase
-
-
-
-
P57-STK
-
-
-
-
P59-FYN
-
-
-
-
p59-HCK/p60-HCK
-
-
-
-
P60-SRC
-
-
-
-
p60-YRK
-
-
-
-
P61-YES
-
-
-
-
p94-FER
-
-
-
-
phosphotyrosyl-protein kinase
-
-
-
-
PP125FAK
-
-
-
-
Protein kinase (tyrosine-phosphorylating)
-
-
-
-
protein kinase A
-
-
-
-
Protein kinase BATK
-
-
-
-
Protein kinase HYL
-
-
-
-
Protein kinase Lck
-
-
-
-
Protein kinase NTK
-
-
-
-
Protein kinase p56-LCK
-
-
-
-
Protein kinase p56lck
-
-
-
-
Protein p56c-lck kinase
-
-
-
-
Protein p56lck tyrosine kinase
-
-
-
-
Protein tyrosine kinase
-
-
-
-
protein tyrosine kinase 2beta
-
-
-
-
Protein tyrosine kinase lck
-
-
-
-
Protein tyrosine kinase p56lck
-
-
-
-
Protein tyrosine kinase pp56lck
-
-
-
-
Protein-tyrosine kinase C-TKL
-
-
-
-
Protein-tyrosine kinase CYL
-
-
-
-
PTK
-
-
-
-
PTK-RL-18
-
-
-
-
PTK70
-
-
-
-
Quek1
-
-
-
-
Related adhesion focal tyrosine kinase
-
-
-
-
Resting lymphocyte kinase
-
-
-
-
Rlk/Txk
-
-
-
-
S-domain receptor-like protein kinase
-
-
-
-
SLK
-
-
-
-
Spleen tyrosine kinase
-
-
-
-
src-kinase
-
-
-
-
SRC-related intestinal kinase
-
-
-
-
Syk-related tyrosine kinase
-
-
-
-
SYN
-
-
-
-
T cell-specific protein-tyrosine kinase
-
-
-
-
T-cell-specific kinase
-
-
-
-
Tyrosine kinase
-
-
-
-
Tyrosine kinase ARG
-
-
-
-
Tyrosine kinase lck
-
-
-
-
Tyrosine kinase p56lck
-
-
-
-
Tyrosine phosphokinase
-
-
-
-
Tyrosine protein kinase
-
-
-
-
Tyrosine protein kinase p56lck
-
-
-
-
Tyrosine-protein kinase brk
-
-
-
-
Tyrosine-protein kinase CTK
-
-
-
-
Tyrosine-protein kinase Lyk
-
-
-
-
Tyrosine-protein kinase TYRO 10
-
-
-
-
Tyrosine-specific protein kinase
-
-
-
-
Tyrosylprotein kinase
-
-
-
-
v-fps Protein-tyrosine kinase
-
-
-
-
WEE1hu
-
-
-
-
YES related kinase
-
-
-
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
phospho group transfer
-
-
-
-
SYSTEMATIC NAME
IUBMB Comments
ATP:[protein]-L-tyrosine O-phosphotransferase (non-specific)
Unlike EC 2.7.10.1, receptor protein-tyrosine kinase, this protein-tyrosine kinase does not have a transmembrane domain. In the human genome, 32 non-specific protein-tyrosine kinases have been identified and these can be divided into ten families [1].
CAS REGISTRY NUMBER
COMMENTARY hide
114051-78-4
p56lck protein kinase
80449-02-1
protein-tyrosine kinase
9026-43-1
this CAS Reg. No. encompasses a great variety of protein kinases including the serine/threonine specific kinases
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
ATP + a [protein]-L-tyrosine
ADP + a [protein]-L-tyrosine phosphate
show the reaction diagram
-
-
-
?
ATP + [Signal Transducer and Activation of Transcription (STAT) protein]-L-tyrosine
ADP + [Signal Transducer and Activation of Transcription (STAT) protein]-L-tyrosine phosphate
show the reaction diagram
-
-
-
?
additional information
?
-
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
ATP + a [protein]-L-tyrosine
ADP + a [protein]-L-tyrosine phosphate
show the reaction diagram
-
-
-
?
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1-(4-((5-methyl-2-((4-morpholinophenyl)amino)pyrimidin-4-yl) amino)piperidin-1-yl)ethan-1-one
100 nM, 70.5% inhibition. 28°C, pH not specified in the publication
1-(4-(5-methyl-2-((4-morpholinophenyl)amino)pyrimidin-4-yl) piperazin-1-yl)ethan-1-one
100 nM, 66.2% inhibition. 28°C, pH not specified in the publication
1-(4-(5-methyl-2-((4-morpholinophenyl)amino)pyrimidin-4-yl) piperazin-1-yl)pentane-1,4-dione
100 nM, 56.4% inhibition. 28°C, pH not specified in the publication
1-(4-(5-methyl-2-((4-morpholinophenyl)amino)pyrimidin-4-yl) piperazin-1-yl)propan-1-one
100 nM, 73.4% inhibition. 28°C, pH not specified in the publication
1-(4-acetylphenyl)-3-(1-(5-methyl-2-((4-morpholinophenyl) amino)pyrimidin-4-yl)azetidin-3-yl)urea
100 nM, 21.9% inhibition. 28°C, pH not specified in the publication
1-(4-acetylphenyl)-3-(1-(5-methyl-2-((4-morpholinophenyl) amino)pyrimidin-4-yl)pyrrolidin-3-yl)urea
100 nM, 57.4% inhibition. 28°C, pH not specified in the publication
2-(4-acetylphenyl)-1-(4-(2-((4-morpholinophenyl)amino)thieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)ethan-1-one
100 nM, 44% inhibition. 28°C, pH not specified in the publication
3-amino-5-((2R)-3-methylbutan-2-yl)-7-[5-(morpholin-4-yl)-pyridin-2-yl]-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
-
3-amino-5-((2S)-3-methylbutan-2-yl)-7-(1-methyl-1H-pyrazol-3-yl)-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
-
3-amino-5-((2S)-3-methylbutan-2-yl)-7-[1-methyl-5-(morpholin-4-yl)-1H-pyrazol-3-yl]-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
-
3-amino-5-((2S)-3-methylbutan-2-yl)-7-[1-methyl-5-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl]-1,5-dihydro-4H-pyrazolo[4,3-c]-pyridin-4-one
-
3-amino-5-((2S)-3-methylbutan-2-yl)-7-[5-(morpholin-4-yl)-pyridin-2-yl]-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
-
3-amino-5-(2-methylpentan-3-yl)-7-(1-methyl-1H-pyrazol-3-yl)-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
-
3-amino-5-(3-methylbutan-2-yl)-7-(1-methyl-1H-pyrazol-3-yl)-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
-
3-amino-5-(3-methylbutan-2-yl)-7-[5-(morpholin-4-yl)pyridin-2-yl]-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
-
3-amino-5-isobutyl-7-(1-methyl-1H-pyrazol-3-yl)-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
-
3-amino-5-sec-butyl-7-(1-methyl-1H-pyrazol-3-yl)-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
-
3-amino-7-[5-(1,1-dioxidothiomorpholin-4-yl)-1-methyl-1H-pyrazol-3-yl]-5-((2S)-3-methylbutan-2-yl)-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
-
3-amino-7-[5-(2-hydroxypropan-2-yl)-1-methyl-1H-pyrazol-3-yl]-5-((2S)-3-methylbutan-2-yl)-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
-
4-(2-(4-(2-((4-morpholinophenyl)amino)thieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)-2-oxoethyl)benzonitrile
100 nM, 17.6% inhibition. 28°C, pH not specified in the publication
4-(4-(cyclopropylsulfonyl)piperazin-1-yl)-5-methyl-N-(4-morpholinophenyl)pyrimidin-2-amine
100 nM, 76.2% inhibition. 28°C, pH not specified in the publication
5-methyl-4-(4-(methylsulfonyl)piperazin-1-yl)-N-(4-morpholinophenyl)pyrimidin-2-amine
100 nM, 1.0% inhibition. 28°C, pH not specified in the publication
8-(1-acetylpiperidin-4-yl)-2-((4-morpholinophenyl)amino)pteridin-7(8H)-one
100 nM, 3.5% inhibition. 28°C, pH not specified in the publication
AZ960
potent and selective ATP competitive inhibitor of JAK2 enzyme activity
cyclopropyl(4-(5-methyl-2-((4-morpholinophenyl)amino)pyrimidin-4-yl)piperazin-1-yl)methanone
100 nM, 77.0% inhibition. 28°C, pH not specified in the publication
INCB018424
Jak2 inhibitor
JAK-inhibitor I
40% JAK2 residual activity in the presence of 0.002 mM JAK-inhibitor I and 0.02 mM ATP
-
LS104
i.e. [(E,E)-2-(benzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrite], non-ATP-competitive small-molecule inhibitor of JAK2, 20% residual activity of mutant V617F in the resence of 0.02 mM LS104 and 0.02 mM ATP
N,N-dimethyl-4-(5-methyl-2-((4-morpholinophenyl)amino)pyrimidin-4-yl)piperazine-1-carboxamide
100 nM, 63.4% inhibition. 28°C, pH not specified in the publication
N-(4-acetylphenyl)-1-(5-methyl-2-((4-morpholinophenyl) amino)pyrimidin-4-yl)piperidine-4-carboxamide
100 nM, 74.3% inhibition. 28°C, pH not specified in the publication
N-(4-acetylphenyl)-3-((5-methyl-2-((4-morpholinophenyl) amino)pyrimidin-4-yl)amino)azetidine-1-carboxamide
100 nM, 8.1% inhibition. 28°C, pH not specified in the publication
N-(4-acetylphenyl)-3-((5-methyl-2-((4-morpholinophenyl) amino)pyrimidin-4-yl)amino)pyrrolidine-1-carboxamide
100 nM, 69.3% inhibition. 28°C, pH not specified in the publication
N-(4-acetylphenyl)-4-((5-methyl-2-((4-morpholinophenyl) amino)pyrimidin-4-yl)amino)piperidine-1-carboxamide
100 nM, 80.5% inhibition. 28°C, pH not specified in the publication
N-(4-acetylphenyl)-4-(2-((4-morpholinophenyl)amino)-5-(trifluoromethyl)pyr-imidin-4-yl)piperazine-1-carboxamide
100 nM, 74.6% inhibition. 28°C, pH not specified in the publication
N-(4-acetylphenyl)-4-(2-((4-morpholinophenyl)amino)-5-nitropyrimidin-4-yl)piperazine-1-carboxamide
100 nM, 68.4% inhibition. 28°C, pH not specified in the publication
N-(4-acetylphenyl)-4-(2-((4-morpholinophenyl)amino)-7-oxopteridin-8(7H)-yl)piperidine-1-carboxamide
100 nM, 2.3% inhibition. 28°C, pH not specified in the publication
N-(4-acetylphenyl)-4-(2-((4-morpholinophenyl)amino)quinazolin-4-yl)piperazine-1-carboxamide
100 nM, 3.2% inhibition. 28°C, pH not specified in the publication
N-(4-acetylphenyl)-4-(5-amino-2-((4-morpholinophenyl)amino) pyrimidin-4-yl)piperazine-1-carboxamide
100 nM, 22.8% inhibition. 28°C, pH not specified in the publication
N-(4-acetylphenyl)-4-(5-chloro-2-((4-morpholinophenyl)amino) pyrimidin-4-yl)piperazine-1-carboxamide
100 nM, 99.4% inhibition. 28°C, pH not specified in the publication
N-(4-acetylphenyl)-4-(5-fluoro-2-((4-morpholinophenyl)amino) pyrimidin-4-yl)piperazine-1-carboxamide
100 nM, 93.5% inhibition. 28°C, pH not specified in the publication
N-(4-acetylphenyl)-4-(5-methyl-2-((4-morpholinophenyl) amino)pyrimidin-4-yl)piperazine-1-sulfonamide
100 nM, 82.4 % inhibition. 28°C, pH not specified in the publication
N-(4-acetylphenyl)-4-(5-methyl-2-((4-morpholinophenyl)amino)pyrimidin-4-yl)piperazine-1-carboxamide
2.9 nM, 81.8% inhibition. 28°C, pH not specified in the publication
N-(4-acetylphenyl)-4-(6-methyl-2-((4-morpholinophenyl)amino)pyrimidin-4-yl)piperazine-1-carboxamide
100 nM, 15.6% inhibition. 28°C, pH not specified in the publication
N-(4-acetylphenyl)-4-[2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl]piperazine-1-carboxamide
27 nM, 86.7% inhibition. 28°C, pH not specified in the publication
N-(4-cyanophenyl)-1-(5-methyl-2-((4-morpholinophenyl) amino)pyrimidin-4-yl)piperidine-4-carboxamide
100 nM, 72.8% inhibition. 28°C, pH not specified in the publication
N-(4-cyanophenyl)-4-(2-((4-morpholinophenyl)amino)quinazolin-4-yl)piperazine-1-carboxamide
100 nM, 9.7% inhibition. 28°C, pH not specified in the publication
N-(4-cyanophenyl)-4-(5-methyl-2-((4-morpholinophenyl)amino)pyrimidin-4-yl)piperazine-1-carboxamide
100 nM, 88.5% inhibition. 28°C, pH not specified in the publication
N-(4-cyanophenyl)-4-(6-methyl-2-((4-morpholinophenyl)amino)pyrimidin-4-yl)piperazine-1-carboxamide
100 nM, 8.9% inhibition. 28°C, pH not specified in the publication
TG101209
Jak2 inhibitor
additional information
JAK2 is not inhibited by STI571
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00014
3-amino-5-((2R)-3-methylbutan-2-yl)-7-[5-(morpholin-4-yl)-pyridin-2-yl]-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
Homo sapiens
37°C, pH not specified in the publication
0.00007
3-amino-5-((2S)-3-methylbutan-2-yl)-7-(1-methyl-1H-pyrazol-3-yl)-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
Homo sapiens
37°C, pH not specified in the publication
0.000014
3-amino-5-((2S)-3-methylbutan-2-yl)-7-[1-methyl-5-(morpholin-4-yl)-1H-pyrazol-3-yl]-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
Homo sapiens
37°C, pH not specified in the publication
0.000012
3-amino-5-((2S)-3-methylbutan-2-yl)-7-[1-methyl-5-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl]-1,5-dihydro-4H-pyrazolo[4,3-c]-pyridin-4-one
Homo sapiens
37°C, pH not specified in the publication
0.000007
3-amino-5-((2S)-3-methylbutan-2-yl)-7-[5-(morpholin-4-yl)-pyridin-2-yl]-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
Homo sapiens
37°C, pH not specified in the publication
0.00083
3-amino-5-(2-methylpentan-3-yl)-7-(1-methyl-1H-pyrazol-3-yl)-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
Homo sapiens
37°C, pH not specified in the publication
0.00031
3-amino-5-(3-methylbutan-2-yl)-7-(1-methyl-1H-pyrazol-3-yl)-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
Homo sapiens
37°C, pH not specified in the publication
0.000013
3-amino-5-(3-methylbutan-2-yl)-7-[5-(morpholin-4-yl)pyridin-2-yl]-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
Homo sapiens
37°C, pH not specified in the publication
0.00039
3-amino-5-isobutyl-7-(1-methyl-1H-pyrazol-3-yl)-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
Homo sapiens
37°C, pH not specified in the publication
0.00018
3-amino-5-sec-butyl-7-(1-methyl-1H-pyrazol-3-yl)-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
Homo sapiens
37°C, pH not specified in the publication
0.000013
3-amino-7-[5-(1,1-dioxidothiomorpholin-4-yl)-1-methyl-1H-pyrazol-3-yl]-5-((2S)-3-methylbutan-2-yl)-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
Homo sapiens
37°C, pH not specified in the publication
0.000017
3-amino-7-[5-(2-hydroxypropan-2-yl)-1-methyl-1H-pyrazol-3-yl]-5-((2S)-3-methylbutan-2-yl)-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one
Homo sapiens
37°C, pH not specified in the publication
0.0000008
baricitinib
Homo sapiens
37°C, pH not specified in the publication
-
0.00093 - 0.00252
LS104
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
levels of Jak2 protein expression increased significantly in mitogen- and anti-IgM-stimulated B cells and to a lesser degree in activated T cells
Manually annotated by BRENDA team
peripheral blood leukocytes
Manually annotated by BRENDA team
skeletal muscle
Manually annotated by BRENDA team
levels of Jak2 protein expression increased significantly in mitogen- and anti-IgM-stimulated B cells and to a lesser degree in activated T cells
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
physiological function
constitutive JAK activation leads to persistent activation of STAT transcription factors, and several cancers exhibit constitutive STAT activation, in the absence of JAK or STAT activating mutations
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION?
JAK2_HUMAN
1132
0
130674
Swiss-Prot
other Location (Reliability: 2)
PDB
SCOP
CATH
UNIPROT
ORGANISM
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
V617F
V617F/C618R
the mutation is associated with polycythemia vera
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
the mutant V617F is expressed in Ba/F3 cells
the V617F mutant is expressed in Ba/F3 cells
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Dalal, I.; Arpaia, E.; Dadi, H.; Kulkarni, S.; Squire, J.; Roifman, C.M.
Cloning and characterization of the human homolog of mouse Jak2
Blood
91
844-851
1998
Homo sapiens (O60674), Homo sapiens
Manually annotated by BRENDA team
Peeters, P.; Raynaud, S.D.; Cools, J.; Wlodarska, I.; Grosgeorge, J.; Philip, P.; Monpoux, F.; Van Rompaey, L.; Baens, M.; Van den Berghe, H.; Marynen, P.
Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia
Blood
90
2535-2540
1997
Homo sapiens (O60674), Homo sapiens
Manually annotated by BRENDA team
Saltzman, A.; Stone, M.; Franks, C.; Searfoss, G.; Munro, R.; Jaye, M.; Ivashchenko, Y.
Cloning and characterization of human Jak-2 kinase: high mRNA expression in immune cells and muscle tissue
Biochem. Biophys. Res. Commun.
246
627-633
1998
Homo sapiens (O60674), Homo sapiens
Manually annotated by BRENDA team
Jedidi, A.; Marty, C.; Oligo, C.; Jeanson-Leh, L.; Ribeil, J.A.; Casadevall, N.; Galy, A.; Vainchenker, W.; Villeval, J.L.
Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines
Blood
114
1842-1851
2009
Homo sapiens (O60674), Homo sapiens
Manually annotated by BRENDA team
Wang, Y.; Fiskus, W.; Chong, D.G.; Buckley, K.M.; Natarajan, K.; Rao, R.; Joshi, A.; Balusu, R.; Koul, S.; Chen, J.; Savoie, A.; Ustun, C.; Jillella, A.P.; Atadja, P.; Levine, R.L.; Bhalla, K.N.
Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells
Blood
114
5024-5033
2009
Homo sapiens (O60674), Homo sapiens
Manually annotated by BRENDA team
Yoo, J.H.; Park, T.S.; Maeng, H.Y.; Sun, Y.K.; Kim, Y.A.; Kie, J.H.; Cho, E.H.; Song, J.; Lee, K.A.; Suh, B.; Choi, J.R.
JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature
Cancer Genet. Cytogenet.
189
43-47
2009
Homo sapiens (O60674), Homo sapiens
Manually annotated by BRENDA team
Apostolidou, E.; Kantarjian, H.M.; Verstovsek, S.
JAK2 inhibitors: A reality? A hope?
Clin. Lymphoma Myeloma
9
S340-S345
2009
Homo sapiens (O60674), Homo sapiens
Manually annotated by BRENDA team
Lipka, D.B.; Hoffmann, L.S.; Heidel, F.; Markova, B.; Blum, M.C.; Breitenbuecher, F.; Kasper, S.; Kindler, T.; Levine, R.L.; Huber, C.; Fischer, T.
LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells
Mol. Cancer Ther.
7
1176-1184
2008
Homo sapiens (O60674)
Manually annotated by BRENDA team
Constantinescu, S.N.; Girardot, M.; Pecquet, C.
Mining for JAK-STAT mutations in cancer
Trends Biochem. Sci.
33
122-131
2008
Homo sapiens (O60674)
Manually annotated by BRENDA team
Li, Y.; Wang, P.; Chen, C.; Ye, T.; Han, Y.; Hou, Y.; Liu, Y.; Gong, P.; Qin, M.; Zhao, Y.
Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3)
Bioorg. Chem.
104
104361
2020
Homo sapiens (O60674)
Manually annotated by BRENDA team
Yogo, T.; Nagamiya, H.; Seto, M.; Sasaki, S.; Shih-Chung, H.; Ohba, Y.; Tokunaga, N.; Lee, G.N.; Rhim, C.Y.; Yoon, C.H.; Cho, S.Y.; Skene, R.; Yamamoto, S.; Satou, Y.; Kuno, M.; Miyazaki, T.; Nakagawa, H.; Okabe, A.; Marui, S.; Aso, K.; Yoshida, M.
Structure-based design and synthesis of 3-amino-1,5-dihydro-4H-pyrazolopyridin-4-one derivatives as tyrosine kinase 2 inhibitors
J. Med. Chem.
59
733-749
2016
Homo sapiens (O60674), Homo sapiens (P23458), Homo sapiens (P29597), Homo sapiens (P52333), Homo sapiens
Manually annotated by BRENDA team